Y.S. Park
University of Illinois Urbana-Champaign · 31 works · 615 citations · h-index 6
Top works
- A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆
- Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
- Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
- Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
- A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
- TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer
- Tumour Shrinkage at 6 Weeks Predicts Favorable Clinical Outcomes in a Phase III Study of Gemcitabine and Oxaliplatin with or Without Erlotinib for Advanced Biliary Tract Cancer
- Gastroenteropancreatic Neuroendocrine Tumors (Gepnet) Registry: Update from an International Collaboration
- Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial
- 618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
- P-104 Multi-center phase III trial of Adjuvant Chemoradiotherapy in Stomach Tumors 2 (ARTIST 2)
- Phase Ii Trial of Epidermal Growth Factor Ointment for Patients with Erlotinib-Related Skin Effects
- 511P Real-world survival outcomes of Asian metastatic colorectal cancer patients undergoing hepatectomy from the AsianmCRCRegistry
- 35P Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
- A phase II study of pemetrexed and erlotinib for metastatic colorectal cancer refractory to standard chemotherapy
- PBE Meets LLM: When Few Examples Aren't Few-Shot Enough
- A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer
- P-145 Prospective Phase II Trial of Combination Treatment of Whole Hepatic Irradiation and Hyperthermia in Chemorefractory Numerous Hepatic Metastases of Gastrointestinal Malignancy
- 105P Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
- P-214 Salvage Chemoradiotherapy for Locally Recurrent Bile Duct Cancer